Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
HORIBA
| Company | HORIBA |
|---|---|
| Name of analyzer | ABX Pentra XL80 |
| Contact | Susan Behnke |
| City, State | Irvine, CA |
| Phone | 888-903-5001 |
| Website | |
| Analyzer application | diagnostic use |
| Dimensions of analyzer (H × W × | 21.5 × 32.3 × 22.4 in./3.35 sq. ft. |
| Country where analyzer was | —/France |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2003/400 |
| First year analyzer sold outside | —/>2, 000 |
| Foreign locations where company | South America, Europe, Asia, Africa, Middle East |
| Human languages (other than | Spanish, Portuguese, French, German, Polish, Russian, Chinese, Japanese |
| Analyzer list price | — (slide maker stainer sold separately) |
| • Analyzer acquisition options | purchase, trade in, lease, reagent rental agreement |
| Training included with purchase/Total time for basic training per operator | — |
| • Follow-up training available | yes (no extra charge) |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, WBC |
| Types of testing FDA cleared or approved for analyzer | blood count analysis |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | PDW, PCT, RDW-SD, ALY#, ALY%, LIC#, LIC% |
| Differential methods used | impedance with hydrofocus cytometry and cytochemistry, flow cytometry double hydrodynamic sequential system |
| Analytical measurement range: • WBC count/RBC count | WBC: 0–120 × 103/μL/RBC: 0–8 × 103/μL |
| Precision: • WBC count/RBC count | WBC: <2.0% CV/RBC: <2.0% CV |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | multiple myeloma, hemolysis, platelet agglutination, chemotherapy, cryoglobulins/agglutinated RBCs, cold agglutinins |
| • Hemoglobin/Platelets | elevated lipemia, increased turbidity/RBC agglutination, chemotherapy, hemolysis, platelet agglutination |
| • Hematocrit/Reticulocytes | RBC agglutination/— |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | —/80 |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | sodium citrate |
| Min. specimen volume open mode/Closed mode/Microsample capability | CBC: 30 μL; CBC with differential: 53 μL/CBC: 30 μL; CBC with differential: 53 μL/yes |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | — |
| Analyzer performs delta checks | no |
| Parameters for which flags may appear | — |
| Analyzer recognizes and holds test results | yes, for follow-up and potential test rerun (parameters for flags to hold samples defined by client or vendor) |
| Scattergram display uses cell-specific color | yes |
| Histogram display uses color with thresholds | yes |
| LIS interface formats supported | proprietary (analyzer or vendor specific), ASTM 1394-91, ASTM 1238-95, ASTM 1381, HL7 version 2, HL7 version 3, IEEE MIB |
| • Middleware interface | no (connects directly to LIS) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, histograms, scatterplots, patient demographics, patient orders, host query for patient demographics and orders |
| Analyzer transmits LOINC codes for results to LIS or middleware | — |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Data Matrix, Code 39, Code 128 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes |
| No. of onboard reagents required for standard specimen analysis | 4 (plus 1 cleaner) |
| • Reagents ready to use/Reagent tracking method | yes/barcode reader |
| Onboard diagnostics for troubleshooting | yes (diagnostic programs limited to software problems) |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/— |
| Notes | — |